PROTON PUMP INHIBITOR RESPONSE — CYP2C19

Proton Pump Inhibitor Response — CYP2C19 determines how quickly PPIs are cleared, creating the difference between H. pylori treatment failure in ultra-rapid metabolizers and drug accumulation with interaction risk in poor metabolizers.

Whole genome sequencing provides the complete CYP2C19 diplotype — the same gene that governs clopidogrel, escitalopram, and PPI metabolism — giving your physician the information to select the right PPI dose before a treatment course fails.

CYP2C19

About this condition

Proton Pump Inhibitor Response — CYP2C19

Proton pump inhibitors (PPIs) — omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole — are among the most frequently prescribed medications worldwide, used for gastroesophageal reflux disease (GERD), peptic ulcer disease, Helicobacter pylori eradication, and prevention of NSAID-induced gastropathy. PPIs are prodrugs that require acid activation in the gastric lumen and are subsequently metabolized primarily by CYP2C19 in the liver. CYP2C19 metabolizer status determines PPI plasma concentrations and, consequently, efficacy and interaction potential.

CYP2C19 ultra-rapid metabolizers (UM) and rapid metabolizers clear PPIs so quickly that plasma concentrations of the active drug fall below the threshold needed for complete acid suppression. In H. pylori eradication therapy — where sustained acid suppression is required for antibiotic efficacy — CYP2C19 UMs have significantly lower eradication rates at standard triple or quadruple therapy PPI doses. Studies in populations with high CYP2C19 UM frequency (particularly East Asians) have demonstrated that double-dose PPI therapy dramatically improves H. pylori eradication rates in UMs. CYP2C19 poor metabolizers (PM), conversely, achieve sustained high PPI plasma concentrations — beneficial for acid suppression but creating drug interaction risk (PPIs compete for CYP2C19 with clopidogrel, some antifungals, and antiepileptics).

CPIC Level A guidelines for CYP2C19 and PPIs recommend considering increased PPI doses for UMs when used for H. pylori eradication or moderate-to-severe GERD. The guidelines note that for standard GERD at standard doses, CYP2C19 genotype has less clinical impact because even UMs may achieve symptomatic control. The pharmacogenomic distinction is most clinically significant for H. pylori eradication, where treatment failure has direct consequences — antibiotic resistance emergence and ulcer recurrence. CYP2C19 is a high-priority pharmacogenomic gene precisely because it governs the response to a diverse range of commonly prescribed medications spanning multiple drug classes.

Gene locus: CYP2C19 (10q23.33)

CYP2C19 governs clopidogrel, PPIs, escitalopram, and multiple other drugs. A complete CYP2C19 diplotype from whole genome sequencing answers the prescribing question for all of these simultaneously — not just the single drug being prescribed today.

CYP2C19 UM status predicts first-course H. pylori eradication failure before it occurs

Standard H. pylori eradication therapy — clarithromycin-based triple therapy or bismuth-based quadruple therapy — uses standard PPI doses designed for the average metabolizer. In CYP2C19 ultra-rapid metabolizers, these doses produce PPI exposures insufficient for complete intragastric acid suppression, reducing antibiotic efficacy and eradication rates from approximately 85-90% to 50-70%. First-course H. pylori eradication failure leads to antibiotic re-treatment with higher resistance risk and extended morbidity. Knowing CYP2C19 UM status before initiating H. pylori therapy allows the prescriber to double the PPI dose in the initial treatment course, achieving efficacy equivalent to extensive metabolizers and avoiding the re-treatment cycle entirely.

One CYP2C19 diplotype result covers every CYP2C19-substrate drug for life

CYP2C19 is one of the most clinically consequential pharmacogenomic genes — it metabolizes PPIs, clopidogrel (CPIC Level A antiplatelet guidance), escitalopram and citalopram (CPIC Level A antidepressant guidance with FDA dose cap), sertraline, voriconazole, and multiple other medications. A patient who takes a PPI today may be prescribed clopidogrel after a cardiac stent next year and escitalopram for mood the year after that. Each of these prescribing decisions involves the same CYP2C19 diplotype. A complete result from whole genome sequencing answers all of these questions at once — the same result that informs PPI dosing also informs antiplatelet selection after cardiovascular events, with no additional testing required.

Proton Pump Inhibitor Response — CYP2C19 determines how quickly PPIs are cleared, creating the difference between H. pylori treatment failure in ultra-rapid metabolizers and drug accumulation with interaction risk in poor metabolizers.

Proton Pump Inhibitor Response — CYP2C19

CYP2C19 governs clopidogrel, PPIs, escitalopram, and multiple other drugs. A complete CYP2C19 diplotype from whole genome sequencing answers the prescribing question for all of these simultaneously — not just the single drug being prescribed today.

CYP2C19 UM status predicts first-course H. pylori eradication failure before it occurs

One CYP2C19 diplotype result covers every CYP2C19-substrate drug for life

Others in Pharmacogenomics

One test. A lifetime of answers.